10-K: Aktis Oncology posts 2025 loss, extends cash runway

Clinical-stage radiopharma Aktis Oncology reported a $63.7M 2025 net loss, strengthened liquidity with a $335.3M January 2026 IPO and Lilly collaboration, and guided cash runway into 2029 as it advances Nectin-4 and B7-H3 programs.

Summary

• Business: Clinical-stage developer of targeted radiopharmaceuticals using miniprotein radioconjugates; lead programs target Nectin-4 (AKY-1189) and B7-H3 (AKY-2519).
• Financials (FY2025): Collaboration revenue $6.497M; R&D expense $67.451M; G&A expense $13.730M; total operating expenses $81.181M; net loss $63.731M; accumulated deficit $156.6M.
• Liquidity: Cash, cash equivalents and marketable securities $226.8M at 12/31/2025; plus $335.3M net proceeds from IPO closed 1/12/2026; management projects cash runway into 2029.
• Shares: 53,403,173 shares of common stock and 1,872,829 shares of Class A common stock outstanding as of 3/10/2026; ticker AKTS on Nasdaq.
• Pipeline milestones: FDA cleared IND for [225Ac]Ac-AKY-1189 in April 2025; U.S. Phase 1b underway, first dose level completed and next level opened in Dec 2025; Fast Track granted Feb 2026; preliminary Part 1 dose-escalation data expected Q1 2027.
• B7-H3 program: FDA cleared INDs for [225Ac]Ac-AKY-2519 and [64Cu]Cu-AKY-2519 in March 2026; multi-site Phase 1b planned to initiate mid-2026; patient imaging/dosimetry readout expected mid-2026.
• Collaboration: Entered Eli Lilly agreement (5/16/2024) with $60.0M upfront cash and $10.0M equity; eligible for up to $525.0M in development/regulatory/launch milestones and up to $630.0M in sales milestones; tiered royalties up to 10%; $1.0M milestone achieved by 12/31/2025.
• Manufacturing & supply: Multiple domestic/international 225Ac isotope suppliers; hybrid internal/external model; internal cGMP facility expected fully operational in H2 2026; expanded Boston lab space by 625 RSF (4/14/2025).
• Operating outlook: Phase 1b for AKY-1189 to expand after dose escalation (UC, TNBC, basket cohort); potential pivotal Phase 2 for accelerated approval subject to data; continued discovery platform advancement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as constructive: strong liquidity post-IPO and Lilly collaboration de-risk execution, while clinical timelines and non-revenue status temper near-term catalysts.

Positives

• Strong liquidity: $226.8M cash, cash equivalents and marketable securities at 12/31/2025, plus $335.3M IPO proceeds in January 2026; runway projected into 2029.
• Lilly partnership validation: $60.0M upfront cash, $10.0M equity, up to $1.155B in potential milestones ($525.0M development/regulatory/launch + $630.0M sales) and up to 10% royalties; $1.0M milestone earned in 2025.
• Lead asset momentum: FDA-cleared IND (April 2025), Phase 1b underway with first dose level completed (Dec 2025); Fast Track Designation (Feb 2026); first efficacy/safety signals expected Q1 2027.
• Second program advancing: FDA-cleared INDs for [225Ac]Ac-AKY-2519 and [64Cu]Cu-AKY-2519 (March 2026); Phase 1b initiation planned mid-2026.
• Manufacturing readiness: Multi-sourced 225Ac supply, hybrid CMO/internal setup, and internal cGMP facility slated for H2 2026 enhances control and redundancy.

Negatives

• No product revenue; FY2025 net loss of $63.731M, with operating expenses up 52% year over year to $81.181M.
• Clinical timelines are long: preliminary AKY-1189 Phase 1b dose-escalation data not expected until Q1 2027.
• High R&D burn: FY2025 R&D expense increased to $67.451M from $40.954M, reflecting pipeline and trial ramp-up.
• Dependence on actinium-225 (225Ac) supply and complex radiopharma logistics (time-limited stability) could constrain development and commercialization.

Risks

• Need for additional funding over time despite current runway; inability to raise capital could delay or reduce programs.
• Clinical risk: safety/efficacy in early trials may not translate to later stages; delays or holds could occur.
• Manufacturing and supply risk: potential inability to secure sufficient 225Ac supply or CMO performance shortfalls; internal cGMP facility execution risk.
• Regulatory risk: approvals inherently uncertain; Project Optimus dose-optimization expectations may require additional studies.
• Competition: numerous companies advancing alpha- and beta-emitting radiopharmaceuticals targeting overlapping indications.
• Intellectual property risk: limited issued patents; platform and candidate patents at early stage; potential third-party IP challenges.
• Operational/logistics risk: radiopharmaceuticals have time-limited stability, increasing fulfillment complexity.
• Cybersecurity and data privacy risks, including potential incidents impacting operations and compliance.
• Decommissioning/decontamination obligations for radiological facilities could be significant at end of life.

Future Outlook

Management plans to advance [225Ac]Ac-AKY-1189 through Phase 1b with preliminary dose-escalation data in Q1 2027 and to initiate the [225Ac]Ac-AKY-2519 Phase 1b mid-2026 following March 2026 IND clearances. The company expects its internal cGMP facility to be operational in H2 2026 and, subject to data, aims to align with FDA on a pivotal Phase 2 for accelerated approval in urothelial cancer and other Nectin-4 expressing tumors.

Management Comments

• Enrollment in the AKY-1189 Phase 1b remains on track, with the first dose level completed and the next dose level open as of December 2025; preliminary Part 1 data are expected in Q1 2027.
• Existing cash, cash equivalents, marketable securities and IPO proceeds are expected to fund operations into 2029.
• The internal cGMP facility is expected to be fully operational in the second half of 2026, enhancing supply chain flexibility and control.
• The Lilly collaboration supports platform expansion, with $60.0 million upfront received and the first development milestone achieved.

Industry Context

StockSavvy.ai notes radiopharmaceuticals are experiencing robust strategic and commercial momentum, evidenced by Novartis’s Pluvicto and Lutathera, and large-cap M&A (e.g., AstraZeneca–Fusion, BMS–RayzeBio, Lilly–POINT). Aktis’s alpha-emitting 225Ac focus and targets (Nectin-4, B7-H3) aim beyond PSMA/SSTR incumbents, but success will hinge on trial readouts, 225Ac supply reliability, and manufacturing execution.

Comparison to Industry Standards

• Liquidity versus peers: Aktis’s projected runway into 2029 post-IPO is stronger than many early clinical biotech peers, supporting multi-asset execution without near-term raises.
• Strategic validation: Partnership economics (Lilly $60M upfront, up to $1.155B milestones, up to 10% royalties) compare favorably to early-stage radiopharma deals and align with recent large-cap commitments (e.g., Lilly–POINT, BMS–RayzeBio).
• Target selection: Nectin-4 validation via Padcev (ADC) de-risks target biology relative to novel targets pursued by competitors (e.g., PSMA/SSTR saturation), though clinical translation to radiopharma remains to be proven.
• Manufacturing readiness: Building internal cGMP capacity by H2 2026 is aligned with best practices set by leaders (Novartis AAA, Telix) to mitigate isotope supply and logistics risks common across the sector.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings disclosed.

Related Party Transactions

• Eli Lilly collaboration: $60.0M upfront, $10.0M equity, eligible for up to $525.0M development/regulatory/launch and up to $630.0M sales milestones; up to 10% royalties; $1.0M milestone achieved by 12/31/2025.
• Royalty Transfer Agreement (8/27/2020) with MPM Oncology Charitable Foundation, Inc. and UBS Optimus Foundation: company to pay a combined 1.0% of annual global net sales for certain pre-IPO IP, subject to customary reductions and term limits.
• Consulting/management services from MPM affiliates; de minimis in 2025, $0.1M in 2024.

Stakeholder Impact

• Shareholders: Significant liquidity post-IPO reduces near-term financing risk but comes with dilution; long-dated data catalysts.
• Employees: New equity plans and facility build-out support growth and retention.
• Patients: Advancing first-in-human Nectin-4 and B7-H3 programs targeting high-need solid tumors.
• Suppliers/CMOs: Continued reliance for clinical manufacturing with potential shift to hybrid model as internal cGMP comes online.
• Collaborators: Lilly collaboration advances discovery programs and provides non-dilutive capital.

Next Steps

• Complete Part 1 dose-escalation for AKY-1189 and present preliminary data in Q1 2027.
• Initiate AKY-2519 Phase 1b mid-2026 following March 2026 IND clearances.
• Bring internal cGMP facility online in the second half of 2026 to support clinical supply.
• Pursue FDA alignment for a potential pivotal Phase 2 for AKY-1189, subject to Phase 1b results.

Key Dates

Recommendation

Strong cash runway and a high-quality Lilly partnership are balanced by early-stage clinical risk and a long wait for key efficacy readouts (Q1 2027). A hold is warranted pending initial clinical signals and manufacturing milestones.

Keywords

radiopharmaceuticals, actinium-225, Nectin-4, B7-H3, miniprotein radioconjugates, AKY-1189, AKY-2519, Phase 1b, Fast Track, Eli Lilly collaboration, IPO, AKTS, Pluvicto, Lutathera, Padcev